Impressive results presented by Joe Jacob MD, MCR at #AUA2024 from SunRISE-1 trial showing 82.8% CR rate at anytime and 12mo DOR 74.6%. Well tolerated. Andrea Necchi Hussein Sweiti, MD IBCG Bladder Cancer Advocacy Network

Already in San Antonio for #AUA2024 and strongly promoting our unique FTS-SURS 2024: Imaging, AI, Focal Therapy and Robotics. Hands-on at its best!! Amer. Urol. Assn. Endourological Society Focal Therapy Society Craig Rogers MD

Excellent and dynamic talks with insightful session of case discussions led by #McGill Uroologic Oncology Visiting Professor Sam S. Chang MD, MBA
McGill University Simon Tanguay

What a fantastic Day 1 of the Canadian Bladder Cancer Forum 2024!
Great talks by Eva Michaud Dr. Bishoy M. Faltas Lum Lab and Mathieu Lupien on the concerted influences of microbiome, metabolomics and epigenetics on cancer journey, and very cool AI based next gen tools!
Thank you all!

#CUASF : OUR VISION To ensure a sustainable thriving urological research community in Canada.
For more information and to apply for grants, click here >>>cuasf.org

Is Radiotherapy + radiosensetizer a good option for BCG Unresponsive MIBC with Cis?
EORTC

⭐A phase II trial is coming... led by Vérane Achard
tombal
@dirixpiet Morgan Roupret and Me.

🙏Please find the protocol here :
sciencedirect.com/science/articl…

⁦Dan Albas MP⁩ thank you for meeting with ⁦Canadian Urological Association⁩ to discuss ways to standardize delivery and access to GU Cancer Care in Canada. ⁦Canadian Urological Association⁩ is The Voice of Urologic Oncology in Canada #UROpedia Canada #CUAclinicaltools

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm. G3/4 AEs of 56% for EVP vs 70% for chemo & CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’

Congratulations Dr Jewett….extremely well deserved honour !!!

We are hiring again!! 📣
We are looking to hire a #research #nurse in our phase I unit. If you are looking to be part of a great and energetic team on the forefront of oncology research, apply below!!

shorturl.at/hjnqS
RI-MUHC @McgillOncology

Congrats Ronald Kool et al Improved survival with neoadjuvant cisp’atin-based chemotherapy prior to #TMT is highly relevant especially as the medical community is increasing the use of TMT among younger and healthier patients

51 years in the making till #GU24 . OS benefit in adjuvant Renal Cancer is finally here. #KYN564

1/4 Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial - ScienceDirect. sciencedirect.com/science/articl…

VESPER Trial: survival endpoints at 5 years in an open-label, randomized, phase 3 study

Overall, ITT, in perioperative setting : no association of OS with dd-MVAC vs GC treatment (64% vs 56%, HR 0·79)

In the NAC subgroup: OS at 5 years improved in the dd-MVAC group (66% vs…

FINALLY - what I have been looking forward to prove for 20 years: the detection performance of DRE for PCa is so weak that we can forego this exam. Hope the guidelines take this evidence to stop recommending DRE for PCa screening/early detection.
sciencedirect.com/science/articl…

We are hiring a scientist (assistant professor) who will focus on #immunology and #bladdercancer McGill Dept of Surg Centre universitaire de santé McGill McGill University strong and supportive academic environment in the wonderful city of @montreal please apply or RT

mcgill.wd3.myworkdayjobs.com/en-US/McGill_C…

Finally, the long-awaited TRAVERSE Prostate Safety Study has just been released.

During 14,304 person-years of follow-up on 5204 men (aged 45-80 years) with hypogonadism in this randomized clinical trial, incidences of high-grade or any prostate cancer, acute urinary retention,…